Clinical trial

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

NCT07636785

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention VMD-102 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-07-16

PhasePHASE1 / PHASE2

Conditions

Hepatocellular Carcinoma (HCC)unresolved

Metastatic Uveal Melanomaunresolved

Renal Cell Carcinoma (RCC)unresolved

Nonsmall Cell Lung Cancerverified · MONDO: tumor suppressor gene on chromosome 11

Colorectal Cancer (CRC)unresolved

Interventions

VMD-102DRUG

Sponsors & collaborators

VM Discovery, Inc.lead sponsor

Mapped research locations

ScottsdaleArizona, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07636785 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.